Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
Frequently asked questions
What sector does Vivos Inc (RDGL) operate in?
Vivos Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Vivos Inc (RDGL) current stock price?
As of the latest data, Vivos Inc stock price is $0.04, with a previous close of $0.04. Vivos Inc gained $0.00 in the last trading session, representing a 0.23% increase.
What is Vivos Inc (RDGL) current market capitalization?
Vivos Inc market cap is approximately 21.84 million.
What is Vivos Inc (RDGL) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
What is Vivos Inc (RDGL) EBITDA?
Vivos Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -633.83 thousand.
Does Vivos Inc (RDGL) pay dividends?
No. Vivos Inc does not pay a dividend.
What is Vivos Inc (RDGL) beta (volatility) score?
Vivos Inc has a beta of -0.715, indicating lower volatility than the overall market.
